Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 6/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.55 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.55 |
| ▸ | CHRNB3 | Q05901 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13861974 | 1.00 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL4359511 | 0.85 | CHRNB4 (0.54) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL521428 | 0.85 | CHRNB4 (0.54) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL20376164 | 0.85 | CHRNB4 (0.54) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL20201664 | 0.84 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL10196599 | 0.84 | CHRNB4 (0.71) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL20201653 | 0.84 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL15946938 | 0.83 | CHRNB4 (0.52) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL10873425 | 0.82 | CHRNB2 (0.59) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL2035662 | 0.81 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9833455-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | SPACEFILL ENTERPRISES LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160303128-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2016-10-20 | — | — | US | disclosed |
| US-9221805-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | Spacefill Enterprises LLP (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303128-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | CHRNB4 3785/4885CHRNA3 3915/4885CHRNB2 2707/4885 |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | CHRNB4 3785/4885CHRNA3 3915/4885CHRNB2 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.